US3624215A - 8-substituted theophyllines as anti-anxiety agents - Google Patents
8-substituted theophyllines as anti-anxiety agents Download PDFInfo
- Publication number
- US3624215A US3624215A US49921A US3624215DA US3624215A US 3624215 A US3624215 A US 3624215A US 49921 A US49921 A US 49921A US 3624215D A US3624215D A US 3624215DA US 3624215 A US3624215 A US 3624215A
- Authority
- US
- United States
- Prior art keywords
- theophylline
- substituted
- theophyllines
- patients
- anxiety agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Definitions
- This invention relates to a method of relieving anxiety in patients in order to restore such patients to a more normal and thus contribute to their physical and mental well being.
- nntianxiety agents Patients suffering from depression manifest one or more of a variety of symptoms. Generally speaking, depressed patients feel incapable of dealing with their responsibilities; they lose interest in their jobs, families and hobbies. The predominant symptoms of depression are hypochondria, anorexia, insomnia, anergia, anhedonia and pessimism. However, some patients suffering from depression are also anxious and nervous. In treating such patients, it is desirable to have a therapeutic agent which has tranquilizing or sedative overtones.
- the present invention provides a method of treating anxious or depressed patients employing compounds which exhibit antidepressant and sedative properties. Accordingly, for the purpose of this disclosure, the ii-substituted theophyllines used herein shall he referred to as nntianxiety agents.
- Theophyllinc and a number of its derivatives have been reported to possess activity as central nervous system stimulants and as diuretics. (Quevauviller, Actualitis Pharmacol. 8: 106-52 (I955). We have'unexpectedly found that certain 8- substituted theophyllines possess activity as sedative antidepressants. Thus, the compounds are generally useful in treating patients who are suffering from anxiety or manifesting other symptoms of depression.
- the compounds useful in the practice of this invention are 8-substituted theophyllines represented by the formula wherein R is C C alkyl or C -C cycloalkyl.
- alkyl refers to both straight and branched chain alkyl such as methyl, ethyl, n-propyl, isopropyl, nbutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl and the like.
- the antidepressant activity of the above compounds was established using the modified DOPA test described by Everett et al., Fed. Proc., 23, 198(1964).
- the compounds are administered to patients exhibiting the symptoms of depression, including anxiety, particularly in patients in need of sedation, in dosages of from 1 to 50 mg./kg. of body weight daily, either in single or divided doses. While the compounds exhibit both oral and parenteral activity, the preferred route of administration is the oral route.
- the compounds of the present invention for use as antidepressant or antianxiety agents can be incorporated in to various pharmaceutically acceptable dosage forms such as tablets, capsules, pills, suspensions and the like, for immediate or sustained release, by combining them with suitable carriers or diluents according to methods well known in the art.
- the dosage forms may include various excipients, binders, fillers, flavoring and sweetening agents, and the like, necessary in the formulation of the desired pharmaceutical preparation.
- the antianxiety agent can be the sole ingredient.
- B-n-Pentyl-theophylline S-Cyclopentyl-theophylline 8-n-Hexyl-theophylline 8 n-Butyl-theophylline 8-iso-Butyl-theophylline ll-Cyclopropyl-theophyllinc 8-n-Heptyl-theophylline
- the B-substituted theophyllines employed in the practice of 5 this invention were prepared according to the methods described by Hager et al., J.Am. Pharm. Assoc., 43, I52 (I954) and by first et al., J. Chem Ber., 93, 99 (I960).
- the active agents can be prepared by reacting 5,6-diamino-l,B-dimethyluracil (commercially available from Aldrich Chemical Company, Milwaukee, Wis.)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method of alleviating anxiety in mammals exhibiting such symptoms by administering from 1 to 50 mg./kg. daily of an 8substituted theophylline.
Description
United States Patent [7 2] Inventors Herman Hal Stein Skokie; Elizabeth Goodsell, Waukegan, both of III. [21] Appl. No. 49,921 [22] Filed June 25, 1970 [45] Patented Nov. 30, 1971 [7 3 1 Assignee Abbott Laboratories North Chicago, Ill.
[54] S-SUBSTITUTED THEOPHYLLINES AS ANTI- ANXIETY AGENTS 4 Claims, No Drawings s21 u.s.c| 424/253 OTHER REFERENCES Quevauviller, Actualitis PharmacoL, 8: 106- 52 1955).
Primary ExaminerStanley .l. Freidman Attorney-Robert L. Niblack ABSTRACT: A method of alleviating anxiety in mammals exhibiting such symptoms by administering from I to 50 mg./kg. daily of an 8-substituted theophylline.
S-SUBSTITUTED TI-IEOPHYLLINES AS ANTI-ANXIETY AGENTS DETAILED DESCRIPTION OF THE INVENTION This invention relates to a method of relieving anxiety in patients in order to restore such patients to a more normal and thus contribute to their physical and mental well being.
Patients suffering from depression manifest one or more of a variety of symptoms. Generally speaking, depressed patients feel incapable of dealing with their responsibilities; they lose interest in their jobs, families and hobbies. The predominant symptoms of depression are hypochondria, anorexia, insomnia, anergia, anhedonia and pessimism. However, some patients suffering from depression are also anxious and nervous. In treating such patients, it is desirable to have a therapeutic agent which has tranquilizing or sedative overtones. The present invention provides a method of treating anxious or depressed patients employing compounds which exhibit antidepressant and sedative properties. Accordingly, for the purpose of this disclosure, the ii-substituted theophyllines used herein shall he referred to as nntianxiety agents.
Theophyllinc and a number of its derivatives have been reported to possess activity as central nervous system stimulants and as diuretics. (Quevauviller, Actualitis Pharmacol. 8: 106-52 (I955). We have'unexpectedly found that certain 8- substituted theophyllines possess activity as sedative antidepressants. Thus, the compounds are generally useful in treating patients who are suffering from anxiety or manifesting other symptoms of depression.
The compounds useful in the practice of this invention are 8-substituted theophyllines represented by the formula wherein R is C C alkyl or C -C cycloalkyl.
The term alkyl, as used herein, refers to both straight and branched chain alkyl such as methyl, ethyl, n-propyl, isopropyl, nbutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl and the like.
The antidepressant activity of the above compounds was established using the modified DOPA test described by Everett et al., Fed. Proc., 23, 198(1964).
In the practice of this invention, the compounds are administered to patients exhibiting the symptoms of depression, including anxiety, particularly in patients in need of sedation, in dosages of from 1 to 50 mg./kg. of body weight daily, either in single or divided doses. While the compounds exhibit both oral and parenteral activity, the preferred route of administration is the oral route.
The compounds of the present invention for use as antidepressant or antianxiety agents can be incorporated in to various pharmaceutically acceptable dosage forms such as tablets, capsules, pills, suspensions and the like, for immediate or sustained release, by combining them with suitable carriers or diluents according to methods well known in the art. In addition to active agent and the carrier or diluent, the dosage forms may include various excipients, binders, fillers, flavoring and sweetening agents, and the like, necessary in the formulation of the desired pharmaceutical preparation. However, in the case of filled capsules, for example, the antianxiety agent can be the sole ingredient.
Illustrative compounds useful in the practice of this invention are:
B-n-Pentyl-theophylline S-Cyclopentyl-theophylline 8-n-Hexyl-theophylline 8 n-Butyl-theophylline 8-iso-Butyl-theophylline ll-Cyclopropyl-theophyllinc 8-n-Heptyl-theophylline The B-substituted theophyllines employed in the practice of 5 this invention were prepared according to the methods described by Hager et al., J.Am. Pharm. Assoc., 43, I52 (I954) and by first et al., J. Chem Ber., 93, 99 (I960). Generally speaking, the active agents can be prepared by reacting 5,6-diamino-l,B-dimethyluracil (commercially available from Aldrich Chemical Company, Milwaukee, Wis.)
O l with an acid of the formula wherein R is C C, alkyl or C -C cycloalkyl. The synthesis is represented by the following reaction sequence.
HgC-N N A The following example further illustrates the present invention.
EXAMPLE 1 marked activity. The results are summarized in table I.
TABLE I Compound Dosage (mg/kg.) Modified DOPA Test Response Elavil 30 2+ il-n-Propyl theophylline 30 3+ B-Cyclopropyl theophylline 30 4+ 8-Cyclopentyl theophylline 30 3+ wherein R is C C, alkyl, or C -C cycloalkyl. cyciogr opyl theophylline. 2. The method of claim 1 wherein the compound is 8-n- 4. The method of claim 1 wherein the compound is 8- propyl theophylline. cxciopentyl theophylline.
3. The method of claim 1 wherein the compound is 8-
Claims (3)
- 2. The method of claim 1 wherein the compound is 8-n-propyl theophylline.
- 3. The method of claim 1 wherein the compound is 8-cyclopropyl theophylline.
- 4. The method of claim 1 wherein the compound is 8-cyclopentyl theophylline.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4992170A | 1970-06-25 | 1970-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3624215A true US3624215A (en) | 1971-11-30 |
Family
ID=21962463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US49921A Expired - Lifetime US3624215A (en) | 1970-06-25 | 1970-06-25 | 8-substituted theophyllines as anti-anxiety agents |
Country Status (1)
Country | Link |
---|---|
US (1) | US3624215A (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4089959A (en) * | 1976-03-31 | 1978-05-16 | Cooper Laboratories, Inc. | Long-acting xanthine bronchodilators and antiallergy agents |
US4755517A (en) * | 1986-07-31 | 1988-07-05 | Warner-Lambert Company | Derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
US4772607A (en) * | 1986-05-20 | 1988-09-20 | Warner-Lambert Company | Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
EP0374808A2 (en) * | 1988-12-22 | 1990-06-27 | Boehringer Ingelheim Kg | Xanthin derivatives having an adenosin-antagonist activity |
US5068236A (en) * | 1989-03-06 | 1991-11-26 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
WO1992000297A1 (en) * | 1990-06-22 | 1992-01-09 | Boehringer Ingelheim Kg | New xanthine derivatives |
EP0590919A1 (en) * | 1992-09-28 | 1994-04-06 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agents for parkinson's disease |
US5484920A (en) * | 1992-04-08 | 1996-01-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
US5599817A (en) * | 1992-11-13 | 1997-02-04 | Boehringer Ingelheim Kg | Xanthine derivatives as diuretic agents |
US5861405A (en) * | 1993-05-03 | 1999-01-19 | The United States Of America As Represented By The Department Of Health And Human Services | S-substituted 1,3,7-trialkyl-xanthine derivatives |
US20090291972A1 (en) * | 2008-01-18 | 2009-11-26 | The Board Of Trustees Of The University Of Illinois | Compositions and Methods Relating to Nuclear Hormone and Steroid Hormone Receptors Including Inhibitors of Estrogen Receptor Alpha-mediated Gene Expression and Inhibition of Breast Cancer |
-
1970
- 1970-06-25 US US49921A patent/US3624215A/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
Quevauviller, Actualitis Pharmacol., 8:106 52 (1955). * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4089959A (en) * | 1976-03-31 | 1978-05-16 | Cooper Laboratories, Inc. | Long-acting xanthine bronchodilators and antiallergy agents |
US4772607A (en) * | 1986-05-20 | 1988-09-20 | Warner-Lambert Company | Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
US4755517A (en) * | 1986-07-31 | 1988-07-05 | Warner-Lambert Company | Derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
EP0374808A2 (en) * | 1988-12-22 | 1990-06-27 | Boehringer Ingelheim Kg | Xanthin derivatives having an adenosin-antagonist activity |
EP0374808A3 (en) * | 1988-12-22 | 1991-05-15 | Boehringer Ingelheim Kg | Xanthin derivatives having an adenosin-antagonist activity |
US5175291A (en) * | 1988-12-22 | 1992-12-29 | Boehringer Ingelheim Kg | Process for preparing 1,3-dipropyl-8-(3-oxocyclopentyl)-xanthine |
US5532368A (en) * | 1988-12-22 | 1996-07-02 | Boehringer Ingelheim Gmbh | Xanthine derivatives with adenosine-antagonistic activity |
US5068236A (en) * | 1989-03-06 | 1991-11-26 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
WO1992000297A1 (en) * | 1990-06-22 | 1992-01-09 | Boehringer Ingelheim Kg | New xanthine derivatives |
US5587378A (en) * | 1992-04-08 | 1996-12-24 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
US5484920A (en) * | 1992-04-08 | 1996-01-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
EP0590919A1 (en) * | 1992-09-28 | 1994-04-06 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agents for parkinson's disease |
US5599817A (en) * | 1992-11-13 | 1997-02-04 | Boehringer Ingelheim Kg | Xanthine derivatives as diuretic agents |
US5861405A (en) * | 1993-05-03 | 1999-01-19 | The United States Of America As Represented By The Department Of Health And Human Services | S-substituted 1,3,7-trialkyl-xanthine derivatives |
US20090291972A1 (en) * | 2008-01-18 | 2009-11-26 | The Board Of Trustees Of The University Of Illinois | Compositions and Methods Relating to Nuclear Hormone and Steroid Hormone Receptors Including Inhibitors of Estrogen Receptor Alpha-mediated Gene Expression and Inhibition of Breast Cancer |
US8871751B2 (en) | 2008-01-18 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0196185B1 (en) | Antiviral nucleosides | |
KR100348775B1 (en) | Immunopotentiator | |
US3624215A (en) | 8-substituted theophyllines as anti-anxiety agents | |
US4812590A (en) | Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma | |
US3624216A (en) | 8-substituted theophyllines as anti-inflammatory agents | |
WO2007075102A1 (en) | Medicinal agent for treating viral infections | |
US3699229A (en) | 2-oxo-5-phenyl-4-oxazolidinone as an anti-depressant agent | |
JPH0572903B2 (en) | ||
JPS5942316A (en) | Sleep trouble therapy | |
US3708593A (en) | Use of l-prolyl l-leucyl glycine amide as an anti-depressant | |
US4303658A (en) | Antiviral pyrazolopyrazines | |
US4857529A (en) | Interferon inducing, anti-vaccinia, and/or anti-influenza compositions | |
US3129137A (en) | Method of inhibiting gastro-intestinal irritation | |
EP0381508B1 (en) | Use of cinnamamide for relaxing muscle tone | |
US3067242A (en) | Di-(n, n-dimethyloctadecylamine) pamoate | |
US3635971A (en) | 3 (3 4-dihydro-3-oxo-2-quinoxalinyl) propionamides | |
US3553267A (en) | 3-dimethylamino-1,2,3,4-tetrahydrofluorene | |
US20240041854A1 (en) | Cold medicine and antiviral medicine | |
US6630477B1 (en) | Therapeutic nucleoside compound | |
US3749780A (en) | Method of treating malaria with 3-(p-chlorophenyl)-6-lower alkylamino or dilower alkylamino-s-tetrazines | |
JPH11310530A (en) | Nitrogen monoxide production inhibitor | |
US3426129A (en) | Treatment of depression of the central nervous system with alkyl esters of 1-aziridinepropionic acid | |
JPH0395116A (en) | Reverse transcriptase-inhibiting composition | |
JPH0449231A (en) | Novel differentiation induction-accelerating agent | |
EP0124150B1 (en) | Benzobicyclononane amino derivatives with anticonvulsive properties |